Structure Therapeutics Doses First Patients in Phase 3 ACCOMPLISH Program, Bolstered by $1.3B Cash Runway
Structure Therapeutics Inc. (NASDAQ: GPCR) has achieved defining clinical and corporate milestones in its once-daily oral small-molecule GLP-1 receptor agonist program. The company’s lead candidate, aleniglipron (GPCR-183), has successfully transitioned into Phase 3 clinical development.
Phase 3 ACCOMPLISH Program Initiation
On August 6, 2026, Structure announced that the first patients have been dosed in its Phase 3 ACCOMPLISH program evaluating aleniglipron for chronic weight management. The program is supported by robust Phase 2b data, which demonstrated up to 16.2% weight loss at 36 weeks with a highly favorable tolerability and safety profile.
Investment bank William Blair noted that aleniglipron has been heavily "derisked" by this data, which is "sufficient . . . to effectively complete in the large and growing small-molecule GLP-1 receptor agonist class."
Future Clinical Readouts (Q4 2026)
In addition to the Phase 3 ACCOMPLISH program, Structure is running multiple complementary trials designed to provide further clinical differentiation. The company expects critical topline data readouts in the fourth quarter of 2026 for:
- 44-Week Body Composition Study: Assessing the specific quality of weight loss (fat loss vs. lean muscle mass preservation).
- 12-Week SWITCH Trial: Assessing the safety and tolerability of transitioning patients from injectable GLP-1 receptor agonists directly to oral aleniglipron.
Financial Position
As a clinical-stage, pre-commercial biotechnology firm, Structure reported $0 in TTM revenue. For the second quarter ending June 30, 2026, the company reported an operating loss of $118.6 million and a net loss of $106.2 million.
As of June 30, 2026, Structure held $272.6 million in cash against $6.2 million in total debt. However, its overall cash runway is substantially larger (exceeding $1.3 billion) when factoring in subsequent capital raises and marketable securities, providing a comfortable runway to fund the entire Phase 3 registrational program. The company’s market capitalization stands at $3.38 billion, with shares trading at $47.37 and an analyst target of $104.77.